or Try an Advanced Search...

    Technical Analysis for CLLS - Cellectis S.A.

    Grade Last Price % Change Price Change
    B 2.82 -2.76% -0.08
    CLLS closed down 2.76 percent on Friday, May 24, 2024, on 34 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Jun 12
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical CLLS trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -2.76%
    Outside Day Range Expansion -2.76%
    Wide Bands Range Expansion -2.76%
    Older End-of-Day Signals for CLLS ...

       Recent Intraday Alerts

    Alert Time
    Down 5% 4 days ago
    Down 3% 4 days ago
    Fell Below Previous Day's Low 4 days ago
    Down 2 % 4 days ago
    Down 1% 4 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CLLS Chart by TradingView
    Basic chart:

    Profile

    Cellectis S.A. Description

    Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Blastoma Leukemia Multiple Myeloma Glioblastoma Hematologic Malignancies Genome Oncogenes Chimeric Antigen Receptor Chronic Lymphocytic Leukemia Lymphocytic Leukemia Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Cell Product Acute Lymphoblastic Leukemia Cellectis

    Is CLLS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 7 AstraZeneca concludes equity investment in Cellectis
    May 2 Cellectis announces CFO departure
    May 2 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
    Apr 29 Cellectis GAAP EPS of -$0.64 misses by $0.43, revenue of $1.99M misses by $14.13M
    Apr 29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
    Apr 22 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
    Apr 10 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
    Apr 8 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
    Jan 22 Cellectis: Pushing A Different Kind Of CAR-T Up The Hill
    Dec 22 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
    See more CLLS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.7735
    52 Week Low 0.9628
    Average Volume 52,421
    200-Day Moving Average 2.47
    50-Day Moving Average 2.74
    20-Day Moving Average 2.96
    10-Day Moving Average 2.97
    Average True Range 0.17
    RSI (14) 46.52
    ADX 18.71
    +DI 20.45
    -DI 24.27
    Chandelier Exit (Long, 3 ATRs) 2.88
    Chandelier Exit (Short, 3 ATRs) 2.85
    Upper Bollinger Bands 3.36
    Lower Bollinger Band 2.55
    Percent B (%b) 0.33
    BandWidth 27.55
    MACD Line 0.05
    MACD Signal Line 0.08
    MACD Histogram -0.0326
    Fundamentals Value
    Market Cap 201.87 Million
    Num Shares 71.6 Million
    EPS -1.41
    Price-to-Earnings (P/E) Ratio -2.00
    Price-to-Sales 8.90
    Price-to-Book 2.88
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.08
    Resistance 3 (R3) 3.08 3.00 3.04
    Resistance 2 (R2) 3.00 2.93 3.00 3.02
    Resistance 1 (R1) 2.91 2.89 2.87 2.91 3.01
    Pivot Point 2.82 2.82 2.80 2.82 2.82
    Support 1 (S1) 2.74 2.76 2.69 2.73 2.63
    Support 2 (S2) 2.65 2.72 2.65 2.62
    Support 3 (S3) 2.56 2.65 2.60
    Support 4 (S4) 2.56